10 Delivery of Peptide Nucleic Acids Using an Argininocalix[4]arene
as Vector. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
Alessia Finotti, Jessica Gasparello, Alessandro Casnati,
Roberto Corradini, Roberto Gambari, and Francesco Sansone
PART IV HYBRID CARRIERS AND OTHER BIO AGENTS
11 Cell-Derived Nanovesicles as Exosome-Mimetics for Drug
Delivery Purposes: Uses and Recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147
Yi-Hsuan Ou, Shui Zou, Wei Jiang Goh, Jiong-Wei Wang,
Matthias Wacker, Bertrand Czarny, and Giorgia Pastorin
12 Hydrogel Beads of Natural Polymers as a Potential Vehicle
for Colon-Targeted Drug Delivery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171
Janarthanan Pushpamalar, Thenapakiam Sathasivam,
and Michelle Claire Gugler
13 Scaffold-Based Delivery of CRISPR/Cas9 Ribonucleoproteins
for Genome Editing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183
Wai Hon Chooi, Jiah Shin Chin, and Sing Yian Chew
14 Correction of Hemoglobin E/Beta-Thalassemia Patient-Derived
iPSCs Using CRISPR/Cas9. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193
Methichit Wattanapanitch
15 CRISPR/Cas9-Mediated GFP Reporter Knock-in in K562
and Raji Cell Lines for Tracking Immune Cell Killing Assay . . . . . . . . . . . . . . . . . . 213
Nontaphat Thongsin and Methichit Wattanapanitch
PART V ANALYZING AND PROFILING GENE EXPRESSION
16 Shotgun Proteomics and Mass Spectrometry as a Tool for Protein
Identification and Profiling of Bio-Carrier-Based Therapeutics
on Human Cancer Cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 233
Syafiq Asnawi Zainal Abidin, Iekhsan Othman,
and Rakesh Naidu
Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 241
viii
Contents
as Vector. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
Alessia Finotti, Jessica Gasparello, Alessandro Casnati,
Roberto Corradini, Roberto Gambari, and Francesco Sansone
PART IV HYBRID CARRIERS AND OTHER BIO AGENTS
11 Cell-Derived Nanovesicles as Exosome-Mimetics for Drug
Delivery Purposes: Uses and Recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147
Yi-Hsuan Ou, Shui Zou, Wei Jiang Goh, Jiong-Wei Wang,
Matthias Wacker, Bertrand Czarny, and Giorgia Pastorin
12 Hydrogel Beads of Natural Polymers as a Potential Vehicle
for Colon-Targeted Drug Delivery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171
Janarthanan Pushpamalar, Thenapakiam Sathasivam,
and Michelle Claire Gugler
13 Scaffold-Based Delivery of CRISPR/Cas9 Ribonucleoproteins
for Genome Editing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183
Wai Hon Chooi, Jiah Shin Chin, and Sing Yian Chew
14 Correction of Hemoglobin E/Beta-Thalassemia Patient-Derived
iPSCs Using CRISPR/Cas9. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193
Methichit Wattanapanitch
15 CRISPR/Cas9-Mediated GFP Reporter Knock-in in K562
and Raji Cell Lines for Tracking Immune Cell Killing Assay . . . . . . . . . . . . . . . . . . 213
Nontaphat Thongsin and Methichit Wattanapanitch
PART V ANALYZING AND PROFILING GENE EXPRESSION
16 Shotgun Proteomics and Mass Spectrometry as a Tool for Protein
Identification and Profiling of Bio-Carrier-Based Therapeutics
on Human Cancer Cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 233
Syafiq Asnawi Zainal Abidin, Iekhsan Othman,
and Rakesh Naidu
Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 241
viii
Contents